Medications for Renal Cell Carcinoma

14 results

  • afinitor - everolimus tablet

    (Everolimus)
    Novartis Pharmaceuticals Corporation
    Afinitor treats advanced HR+/HER2- breast cancer (with exemestane), progressive neuroendocrine tumors (pancreatic, GI, or lung), advanced renal cell carcinoma, and tuberous sclerosis complex (TSC)-associated renal angiomyolipoma, SEGA, and partial-onset seizures in adults and pediatric patients.
    Medication Details
    Drug Interactions

  • avastin - bevacizumab injection, solution

    (Bevacizumab)
    Genentech, Inc.
    Avastin (bevacizumab) is a VEGF inhibitor used with chemotherapy to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, ovarian/fallopian tube/peritoneal cancer, and hepatocellular carcinoma. Also indicated for recurrent glioblastoma in adults.
    Medication Details
    Drug Interactions

  • bavencio - avelumab injection, solution, concentrate

    (Avelumab)
    Emd Serono, Inc.
    Bavencio (avelumab) is a PD-L1 blocking antibody indicated for metastatic Merkel cell carcinoma (adults and patients 12+), locally advanced or metastatic urothelial carcinoma (maintenance after platinum chemotherapy or following progression on platinum chemotherapy), and advanced renal cell carcinoma (first-line, with axitinib).
    Medication Details
    Drug Interactions

  • cabometyx - cabozantinib tablet

    (Cabozantinib)
    Exelixis, Inc.
    Cabometyx treats advanced renal cell carcinoma (alone or with nivolumab), hepatocellular carcinoma after sorafenib, and locally advanced or metastatic differentiated thyroid cancer or neuroendocrine tumors (pancreatic and extra-pancreatic) in adults and patients 12 and older after prior therapy.
    Medication Details
    Drug Interactions

  • inlyta - axitinib tablet, film coated

    (Axitinib)
    Pfizer Laboratories Div Pfizer Inc
    Inlyta (axitinib) treats advanced renal cell carcinoma (RCC): in combination with avelumab or pembrolizumab as first-line therapy, or as a single agent after failure of one prior systemic therapy.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    KEYTRUDA is a PD-1 blocking antibody that treats multiple cancers—including melanoma, lung, head and neck, bladder, colorectal, gastric, cervical, breast, and renal cancers—as well as MSI-H/dMMR and TMB-H solid tumors, used across neoadjuvant, adjuvant, and metastatic settings.
    Medication Details
    Drug Interactions

  • lenvima - lenvatinib capsule

    (Lenvatinib)
    Eisai Inc.
    LENVIMA treats adults with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) in pMMR or non-MSI-H patients who progressed after prior therapy.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions

  • sutent - sunitinib malate capsule

    (Sunitinib Malate)
    Pfizer Laboratories Div Pfizer Inc
    Sutent is a kinase inhibitor for adults with gastrointestinal stromal tumor (GIST) after imatinib failure or intolerance, advanced renal cell carcinoma (RCC), adjuvant high-risk RCC after nephrectomy, and progressive unresectable locally advanced or metastatic pancreatic neuroendocrine tumors (pNET).
    Medication Details
    Savings Programs
    1
    Drug Interactions